Achieve Life Sciences (NASDAQ:ACHV – Get Rating) released its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.07, Yahoo Finance reports. During the same period last year, the firm earned ($0.76) earnings per share.
Achieve Life Sciences Price Performance
Shares of NASDAQ ACHV opened at $4.35 on Friday. The business’s 50 day moving average is $4.83 and its 200-day moving average is $3.63. Achieve Life Sciences has a 1-year low of $2.00 and a 1-year high of $8.13. The company has a current ratio of 3.03, a quick ratio of 3.03 and a debt-to-equity ratio of 15.10. The firm has a market cap of $77.87 million, a P/E ratio of -1.09 and a beta of 1.44.
Analyst Upgrades and Downgrades
Separately, Oppenheimer reaffirmed an “outperform” rating and issued a $17.00 price objective on shares of Achieve Life Sciences in a research report on Friday.
Hedge Funds Weigh In On Achieve Life Sciences
A number of hedge funds have recently added to or reduced their stakes in ACHV. Raymond James & Associates increased its stake in Achieve Life Sciences by 412.0% during the 4th quarter. Raymond James & Associates now owns 89,249 shares of the biopharmaceutical company’s stock worth $219,000 after acquiring an additional 71,818 shares during the period. LPL Financial LLC increased its stake in shares of Achieve Life Sciences by 48.4% in the 4th quarter. LPL Financial LLC now owns 148,300 shares of the biopharmaceutical company’s stock valued at $363,000 after purchasing an additional 48,400 shares during the last quarter. Millennium Management LLC bought a new position in shares of Achieve Life Sciences in the 4th quarter valued at $75,000. Jane Street Group LLC bought a new position in shares of Achieve Life Sciences in the 3rd quarter valued at $53,000. Finally, Renaissance Technologies LLC increased its stake in shares of Achieve Life Sciences by 57.5% in the 2nd quarter. Renaissance Technologies LLC now owns 39,700 shares of the biopharmaceutical company’s stock valued at $194,000 after purchasing an additional 14,500 shares during the last quarter. Institutional investors own 21.11% of the company’s stock.
About Achieve Life Sciences
Achieve Life Sciences, Inc is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products includes cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.
Read More
Receive News & Ratings for Achieve Life Sciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Achieve Life Sciences and related companies with MarketBeat.com’s FREE daily email newsletter.